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ABSTRACT
The relationship of age and previous BCG vaccination with tuberculin skin test (TST) reactivity was
investigated to assess the interpretation of TST results in the adult population of Turkey, where there is a
high prevalence of tuberculosis and a routine BCG vaccination programme. The influences of age and
BCG vaccine status on booster reaction were also evaluated. TST was applied (5 tuberculin units of
purified protein derivative intradermally) to two healthy adult groups, namely 98 medical students and
187 elderly people in a retirement home. The TST was considered positive if an induration ‡ 10 mm in
diameter was produced. Subjects (41 elderly people and 39 students) with a reaction < 10 mm in
diameter were retested 1 week later. There was no significant difference between the students (59.1%)
and elderly subjects (58.8%) with respect to positive TST response. No influence of BCG scars on TST
reactivity was observed in either group. The booster effect was seen more commonly in the elderly, but
the presence of a BCG scar did not influence the booster effect in either group. It was concluded that a
positive TST response and booster reaction in adults in high-prevalence countries may be caused by
latent tuberculosis rather than previous vaccination.
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INTRODUCTION
Almost one-third of the world’s population is
infected with Mycobacterium tuberculosis, with an
increase of up to 1% new cases being reported
each year [1]. In 2001, the annual tuberculosis rate
in Turkey was c. 26 ⁄ 100 000 population [2]. The
Turkish Ministry of Health has aimed to prevent
tuberculosis since 1953 with a routine national
immunisation programme for newborn children.
Until 1998, a first BCG vaccination in the newborn
period was repeated after 7, 10 and 17 years
following a negative (< 10 mm) tuberculin skin
test (TST). After 1998, only two doses were used,
the first within 2 months of birth and the second at
the age of 7 years.
The TST is still used widely for detection of
mycobacterial infections, although several novel
diagnostic assays have been developed in recent
years. However, TST reactivity may also be
observed after BCG vaccination. Factors such as
the age at vaccination, time interval, number of
doses and booster effect of natural infection affect
the TST reactivity associated with BCG vaccin-
ation [3–9]. There is no reliable way to distinguish
between a reaction associated with vaccination
and a reaction caused by M. tuberculosis infection.
Following the challenge of unvaccinated subjects
with 5 tuberculin units (TU) of purified protein
derivative (PPD), many workers consider that an
induration of > 10 mm is positive; however, the
significance of a positive reaction in previously
vaccinated subjects is still debatable [4,5,7,9,10].
There is a particular need to define the signifi-
cance of TST results in countries, such as Turkey,
that have a high prevalence of infection and a
routine BCG vaccination programme.
A single TST may not be satisfactory for the
assessment of immunity against M. tuberculosis.
The immune response may gradually weaken in
adults who were vaccinated with BCG or exposed
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to M. tuberculosis in childhood, resulting in a
negative TST response. A repeated test can restore
this reactivity. The booster effect of a second test
is observed most strongly 1–5 weeks following
the first TST, although the effect is thought to
continue for as long as 1 year [11]. However, the
TST should be repeated within 1–3 weeks in
patients with an initial negative TST result [12].
The present study is the first in Turkey to
evaluate the TST reactivity and booster effect in
two healthy adult populations belonging to
discrete age groups. The study aimed to deter-
mine the relationship of age and previous BCG
vaccination with TST reactivity, and also the
influence of age and vaccine status on the
booster reaction.
MATERIALS AND METHODS
TSTs were applied in October 2000 to adult subjects divided
into two discrete groups, namely first-year medical students
and elderly individuals at a retirement home in Ankara. The
students completed self-administered questionnaires to
record demographic data such as age and history of
exposure to tuberculosis. A similar questionnaire for the
elderly subjects was completed with the help of investiga-
tors. All subjects with a history of tuberculosis treatment,
current immunosuppressive treatment, immunisation with
live vaccine within the last 8 weeks, or any circumstance
causing an immunocompromised state, were excluded.
There was no evidence for active tuberculosis or silent
carriage in the study subjects. The presence of a typical BCG
scar was accepted as an indicator of past vaccination. BCG
scars were identified on the upper third of the arm, usually
no more than 4 cm below the shoulder vertex. No TST had
been performed on study subjects in the preceding year to
their knowledge.
The TST was performed by an experienced physician. Five
TU of PPD solution (Biocinetest-PPD; Chiron, Siena, Italy) was
used for the test. A steel needle of 27 gauge attached to a 1-mL
syringe was used to administer 0.1 mL PPD solution intrad-
ermally on the volar surface of the forearm. Subjects were
instructed not to scratch or moisten the test area. The
induration margins were interpreted by the same physician
using the pen method. The test was considered positive if a
reactive induration exceeded 10 mm in diameter. Subjects with
an induration of < 10 mm underwent a second test 1 week
later. The booster effect was considered positive if the
induration on the second test was > 10 mm and at least
6 mm greater than that on the original test. The TST results
were analysed according to age and the presence of a BCG scar
with the chi-square test.
RESULTS
The retirement home had 302 elderly residents. Of
these, 25 were unavailable during the study
period, 31 suffered from severe dementia and
were unable to respond to queries, and 59 did not
consent to the test, leaving 187 study subjects
aged 60–100 years. The student group comprised
98 first-year medical school residents aged
17–21 years. A positive reaction (‡ 10 mm) was
observed in 58 (59.1%) students and 110 (58.8%)
elderly subjects (p > 0.05). The mean induration
diameter was 8.6 ± 6.0 mm (0–20 mm) in stu-
dents and 8.7 ± 6.9 mm (0–32 mm) in the elderly
group. At least one BCG scar was present in 82
(83.6%) students and 37 (19.7%) elderly subjects,
and nine students and two elderly subjects pos-
sessed double scars. The presence of BCG scars
did not influence the TST response in either group
(Table 1).
Only one of 40 students with a negative TST
response (< 10 mm) and 36 of 77 elderly subjects
refused to undergo a second test. Thus, 41 elderly
subjects and 39 students received the second test.
The booster effect on both groups is shown in
Table 2. The ‘negative’ results included eight
elderly subjects and two students who had an
induration that was at least 6 mm larger com-
pared to the first test, but which did not exceed
10 mm. Overall, the booster effect was more
common in the elderly group, but the presence
of a BCG scar did not influence the booster effect
significantly in either group. Table 3 shows that
the booster effect diminished gradually with
increasing age in the elderly group, but this effect
was not statistically significant (p > 0.05).
Table 1. TST responses according to BCG scar presence
Group
No. (%) with diameter of
PPD induration:
TotalScar 0 mm 1–9 mm > 10 mm
Students Absent 2 (12.5) 4 (25.0) 10 (62.5) 16
Present 15 (18.3) 19 (23.1) 48 (58.5) 82
Total 17 (17.3) 23 (23.4) 58 (59.1) 98
Elderly Absent 12 (18.0) 45 (30.0) 93 (62.0) 150
Present 6 (16.2) 14 (37.8) 17 (45.9) 37
Total 18 (9.6) 59 (31.5) 110 (58.8) 187
Table 2. Distribution of the booster effect between groups
No. showing booster effect (%)
p value
Elderly Students
Positive Negative Positive Negative
Scar Present 3 (30.0) 7 (70.0) 1 (3.0) 32 (97.0) < 0.05
Absent 13 (41.9) 18 (58.1) – 6 (100) < 0.05
Total 16 (39.0) 25 (61.0) 1 (2.6) 38 (97.4) < 0.05
p value > 0.05 > 0.05 > 0.05 > 0.05
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No active cases of tuberculosis were reported in
the succeeding 3 years in either the elderly sub-
jects in the retirement home or the medical
students.
DISCUSSION
There have been many previous studies of TST
positivity in adult populations, with rates of
> 30% being reported in high-prevalence coun-
tries [6,9,13]. The present study also detected high
positive rates in students and elderly subjects of
59.1% and 58.9%, respectively. However, none of
the positive TST subjects had any signs of active
tuberculosis during the study period and, as
found in other studies [14–16], none developed
disease within 3 years. These data suggested that
a high positive TST response rate was linked with
a high prevalence of infection, but that it did not
predict the development of active tuberculosis in
the short term.
The positive TST response rate increases with
age, whether or not there has been previous
vaccination with BCG [6,8]. TST positivity rates
were reported to be 42% among subjects aged
> 75 years, compared with 3.1% in college and
university students in the USA [15,17]. In a
previous study from Turkey, a TST response of
> 10 mm was reported for 67.3% of 2835 subjects
aged 6–82 years, with a particular increase in the
positive rate for subjects aged > 18 years [18]. The
present study found high positive rates in both
age groups studied, with no statistical difference.
The high positive rates may be a result of the high
prevalence of tuberculosis in Turkey. In addition,
TST positivity associated with neonatal BCG
vaccination may be superimposed on the immu-
nity that develops following natural infection
with increasing age. Cross-reactions caused by
the presence of atypical mycobacteria are another
possibility, but there are limited data in Turkey
regarding the incidence of atypical mycobacterial
infections.
A typical scar forms in 90–95% of individuals
following BCG vaccination [19]. As in other
studies, the presence of a BCG scar was accepted
as an indicator of previous vaccination. Among
the students, 83.6% had a BCG scar as a result of
the routine vaccination programme. However,
only 19.7% of the elderly subjects had BCG scars,
which might be attributed to limited catch-up
vaccination campaigns, or specific events such as
military service or work in a health care facility.
Previous BCG vaccination is one of the most
common reasons for false-positive TST reactions.
A positive TST reaction of > 10 mm, which devel-
ops in 90% of subjects within 3 months of
immunisation, may decrease with time [4]. This
period is reported to vary from 1 to 25 years, but
BCG-induced positive TST reactivity lasts longer
following immunisation in adulthood [9]. Some
reports suggest that a TST response of > 10 mm in
adults cannot be linked reliably with neonatal
immunisation in low-prevalence countries [4,20].
In a meta-analysis, it was reported that a TST
reaction of > 15 mm was unlikely to be the result
of BCG vaccination if 15 years had elapsed [10].
However, evaluation of TST reactions in immu-
nised subjects in high-prevalence countries is
controversial [9]. The present study observed no
influence of BCG scar on TST response in either
age group, which may indicate that TST positivity
in the adult population was related to natural
infection rather than previous vaccination. There-
fore, detection of TST positivity in adults living
in countries with routine vaccination should
not necessarily be attributed to previous BCG
vaccination, and the individual should be evalu-
ated for tuberculosis.
Repeating the TST for the diagnosis of latent
tuberculosis increases the sensitivity of the test
method. An individual should be considered as
previously infected if a positive reaction is
observed after the second test. The booster effect
associated with repeated TSTs is encountered
more frequently in elderly subjects [21]. Van den
Brande and Demedts [22] observed that 29% of
elderly subjects reacted in the first test, increasing
to 43% following the second test. In addition, a
decreasing booster effect with increasing age was
found. The present study also observed a slight
decrease in the booster effect with increasing age,
but this was not statistically significant.
Another major determinant of the booster effect
is a history of previous BCG vaccine exposure
Table 3. Frequency of the booster effect according to age
groups in the elderly population
Age group
(years)
Booster effect (%)
TotalNegative Positive
60–69 3 (37.5) 5 (62.5) 8
70–79 9 (60) 6 (40) 15
80 + 13 (72.2) 5 (27.8) 18
Total 25 (61) 16 (39) 41
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[23,24]. Menzies et al. [25] studied a group of
students and found a statistically significant
difference for the booster reaction between previ-
ously vaccinated (10.1%) and unvaccinated stu-
dents (2.5%). A similar correlation was not found
in the present study, possibly because age is a
stronger determinant of the booster effect in high-
prevalence countries.
In conclusion, interpretation of a positive TST
response in an individual should take local
epidemiological data into account. In this study,
the positive TST reaction rate was found to be
high in adult populations, irrespective of BCG
immunisation. These findings suggest that a
positive TST response and the booster reaction
in high-prevalence countries are usually caused
by latent tuberculosis rather than previous
vaccination. Thus, the results support the WHO
recommendations [26] that, while TST is a
useful diagnostic method, revaccination is not
recommended and TST should not be used for
this purpose.
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